Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
MLLT1
REST API REST API
Homo sapiens
MLLT1 is differentially expressed in 205 experiments: 99 organism parts: placenta, ovary, ... (97 more);, 145 disease states: normal, control, ... (143 more);, 62 cell types 254 cell lines 24 compound treatments and 65 other conditions.
Synonyms LTG19, ENL, YEATS1
Orthologs MLLT1 (Gallus gallus)   mllt1 (Danio rerio)   MLLT1 (2 of 2) (Danio rerio)   Mllt1 (Mus musculus)   MLLT1 (Bos taurus)   ENSCING00000006124 (Ciona intestinalis)   ear (Drosophila melanogaster)   mllt1 (Xenopus laevis)   MLLT1 (Canis familiaris)   (Compare orthologs)
InterPro Term YEATS
Gene Ontology Term DNA binding, protein binding, regulation of transcription, DNA-dependent, cytoplasm, negative regulation of protein kinase activity, transcription from RNA polymerase II promoter, nucleus, nucleolus
UniProt Accession Q03111
Search EB-eye ENSG00000130382
Show more properties
Experimental Factors
Organism part

studied in E-AFMX-5, E-GEOD-6573, E-MTAB-24, E-MTAB-25, E-GEOD-1563, ... (17 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-2450, E-MTAB-62, ... (28 experiments)

Factor Value U/D Experiments
A549
2
E-GEOD-6013, E-GEOD-3202
SW480
2
E-MEXP-1014, E-MTAB-37
Toledo
1
E-MTAB-37
MCF10A
1
E-MTAB-62
ht-29
1
E-MTAB-62
UT-15
1
E-GEOD-17347
248 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-22373, E-GEOD-3920, E-GEOD-20677, E-GEOD-13909, ... (33 experiments)

Factor Value U/D Experiments
n/a
1
E-MTAB-24
human foreskin fibroblast
1
E-GEOD-18147
naive B cell
1
E-TABM-702
squamous cell carcinoma
1
E-GEOD-17347
ovarian cancer
1
E-GEOD-21154
primary T lymphocytes
1
E-GEOD-13909
56 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-2508, E-GEOD-15960, E-GEOD-1869, E-MEXP-2069, ... (44 experiments)

Factor Value U/D Experiments
adrenocortical carcinoma
2
E-TABM-311, E-GEOD-10927
pancreatic carcinoma
2
E-MTAB-37, E-MEXP-1121
lung adenocarcinoma
2
E-MTAB-37, E-MTAB-62
obesity
2
E-MTAB-62, E-GEOD-2508
uterine fibroid
2
E-MTAB-62, E-GEOD-7307
Chromophobe renal cell carcinoma
1
E-GEOD-19982
139 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-6907, E-GEOD-15205, E-TABM-782, E-GEOD-5824, ... (18 experiments)

Factor Value U/D Experiments
none
2
3
E-GEOD-5824, E-TABM-782, E-GEOD-412, E-GEOD-7400, E-GEOD-20719 ... (5 experiments)
vanadium pentoxide
1
E-GEOD-5339
unknown
1
E-GEOD-7307
interferon-gamma + lipopolysaccharide
1
E-GEOD-5099
sapphyrin PCI-2050
1
E-GEOD-6400
ethanol
1
E-MEXP-2241
18 more value(s).


Age at diagnosis

studied in E-GEOD-4922

Factor Value U/D Experiments
49 years
1
1
E-GEOD-4922


Agent
studied in E-GEOD-19519

Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-17189, E-GEOD-16363

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, E-MTAB-62 ... (5 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-21138

Environmental stress
studied in E-GEOD-1643

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-17385, E-GEOD-20847, E-MEXP-563

Genotype
studied in E-TABM-1029, E-GEOD-17476, E-TABM-321, E-TABM-43, E-TABM-868, ... (7 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-127, E-GEOD-22278, E-GEOD-9764, E-GEOD-10315, E-MEXP-1103, ... (6 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-MEXP-2069, E-TABM-666, E-GEOD-19519, ... (24 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-GEOD-9723, E-MEXP-561 ... (5 experiments)

Injury
studied in E-GEOD-19743

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-GEOD-1657

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-1880, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

RNAi
studied in E-GEOD-12438, E-MEXP-101, E-GEOD-3697, E-MEXP-1857

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-21374, E-GEOD-17400, E-GEOD-18995 ... (5 experiments)

Sex
studied in E-GEOD-19069, E-GEOD-7307, E-GEOD-16363

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Test result
studied in E-TABM-276

Tissue
studied in E-GEOD-30573

Treatment
studied in E-GEOD-19246

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4271, E-TABM-43

weight of protein recovered
studied in E-GEOD-21918

Processing time: 0.328 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM